Last reviewed · How we verify

TR-701 FA with Tyramine

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Phase 1 active Small molecule

TR-701 FA with Tyramine is a Small molecule drug developed by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). It is currently in Phase 1 development. Also known as: Tedizolid Phosphate.

At a glance

Generic nameTR-701 FA with Tyramine
Also known asTedizolid Phosphate
SponsorTrius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TR-701 FA with Tyramine

What is TR-701 FA with Tyramine?

TR-701 FA with Tyramine is a Small molecule drug developed by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Who makes TR-701 FA with Tyramine?

TR-701 FA with Tyramine is developed by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (see full Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline at /company/trius-therapeutics-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa).

Is TR-701 FA with Tyramine also known as anything else?

TR-701 FA with Tyramine is also known as Tedizolid Phosphate.

What development phase is TR-701 FA with Tyramine in?

TR-701 FA with Tyramine is in Phase 1.

Related